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Engineered nanoparticles with theranostic functions have attracted a lot of attention for their potential
role in the dawning era of personalized medicine. Iron oxide nanoparticles (IONPs), with their advan-
tages of being non-toxic, biodegradable and inexpensive, are candidate platforms for the buildup of
theranostic nanostructures; however, progress in using them has been limited largely due to inefficient
drug loading and delivery. In the current study, we utilized dopamine to modify the surface of IONPs,
yielding nanoconjugates that can be easily encapsulated into human serum albumin (HSA) matrices
(clinically utilized drug carriers). This nanosystem is well-suited for dual encapsulation of IONPs and
drug molecules, because the encapsulation is achieved in a way that is similar to common drug loading.
To assess the biophysical characteristics of this novel nanosystem, the HSA coated IONPs (HSA-IONPs)
were dually labeled with 64Cu-DOTA and Cy5.5, and tested in a subcutaneous U87MG xenograft mouse
model. In vivo positron emission tomography (PET)/near-infrared fluorescence (NIRF)/magnetic reso-
nance imaging (MRI) tri-modality imaging, and ex vivo analyses and histological examinations were
carefully conducted to investigate the in vivo behavior of the nanostructures. With the compact HSA
coating, the HSA-IONPs manifested a prolonged circulation half-life; more impressively, they showed
massive accumulation in lesions, high extravasation rate, and low uptake of the particles by macrophages
at the tumor area.
Published by Elsevier Ltd.1. Introduction
Iron oxide nanoparticles (IONPs) are an important class of
biomaterials with extensive usefulness in biomedicine, such as
serving as contrast agents in magnetic resonance imaging (MRI)
[1–4]. Recently, IONPs have been actively investigated as nanoplat-
forms on which to construct probes containing multiple imaging
motifs [5–9], with several successful attempts already reported by us
and other groups [10,11]. An even more ambitious goal is to load
drugs into these nanosystems to achieve all-in-one theranostic
agents that integrate manifold capabilities, including diagnostic
imaging, drug delivery, and therapeutic monitoring. Theranostics
offer great potential in the dawning era of personalized medicineImaging and Nanomedicine
and Bioengineering (NIBIB),
1C22, Bethesda, MD 20892,
Ltd.[12] by affording simultaneous therapy and monitoring. IONPs, with
their advantages of non-toxicity, biodegradability and inexpensive-
ness, have been proposed as candidate materials for the buildup of
theranostics, but progress has been limited. To work efficiently, the
drug vehicles must have a reasonable circulation time, good lesion
accumulation rate and high extravasation rate. However, conven-
tional IONPs suffer from a relatively large size (hydrodynamic size
>50 nm [13]) as well as mutual magnetic attraction, making them
susceptible to acute hepatic accumulation and poor extravasation
rates [13]. More critically, unlike other potential vehicles – such as
carbon nanotubes [14], which afford unique molecule docking
mechanisms – the IONP surface is unfavorable for drug loading. To
date, most drug loading with IONPs has been achieved by covalent
linking [13,15,16], which is inefficient and suboptimal for drug
release.
One solution is to dope IONPs into molecular matrices with
known drug loading capacity. Instead of serving as hosts, the
IONPs are co-guests with drug molecules, and are both encapsu-
lated. One such example was recently given by Yu et al. who
utilized poly(TMSMA-r-PEGMA) to modify IONPs, and then loaded
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agents with combined cancer imaging and therapy capacities [17].
However, the loading efficiency of such a system is not necessarily
high, and its clinical translation prospective is unknown.
On the other hand, even though protein based vehicles, such as
HSA, have long been utilized for drug delivery purposes [18], they
have seldom been used to form theranositc agents with IONPs [11].
HSA has proven to be useful in extending the drug molecules’
circulation half-lives and improving their tumor homing rate.
Particularly, HSA-bound paclitaxel (Abraxane) has demonstrated
enhanced response rate and tumor regression compared with
solvent based paclitaxel (PTX), and has been approved by FDA for
chemotherapy. HSA drug loading is typically achieved by adding
drugs in polar solvent into HSA aqueous solution [19]. This, however,
is impractical with common IONPs, which are made by co-precipi-
tation or pyrolysis, because they are either too hydrophilic or
hydrophobic to form reliable complexes.
In the current study, we produced pyrolysis-derived IONPS with
moderate polarity by modifying them with dopamine, and these
were easily encapsulated into HSA matrices in a way similar to PTX
loading. Such HSA-IONPs were labeled with Cy5.5 dye [20] and 64Cu-
DOTA chelates (Fig. 1), and injected into a subcutaneous U87MG
xenograft mouse model. NIRF/PET/MRI imaging and histopathology
were performed to understand the particles’ pharmacokinetics and
to evaluate their potential role as theranostic platforms.
2. Materials and methods
2.1. Nanoparticle preparation
Oleate coated IONPs with a diameter of 15 nm were obtained from Ocean
NanoTech (Springdale, AR). For surface modification, about 5 mg of oleate coated
nanoparticles was dispersed in 5 ml of chloroform, then 20 mg dopamine in 2 ml
dimethyl sulfoxide (DMSO) was added into the solution, and the mixture was stirred
to form a homogeneous solution. After heating at 70 C for 1 h, the mixture was
cooled down to room temperature, and the particles were collected via centrifu-
gation at 15,000 g for 15 min. Subsequently, the particles were blown dry under
nitrogen flow, and redispersed in DMSO with the aid of sonication. In parallel, 50 mg
HSA was dissolved in 30 ml borate buffer (50 nM, pH 8.5) to make an HSA solution.
With sonication, the nanoparticles in DMSO were added dropwise to the HSA
solution. The solution was then centrifuged at 30,000 g for 20 min (3) to remove
the free HSA, and the collected particles were redispersed in phosphate buffered
saline (PBS) and dialyzed against PBS (MWCO 10,000). A small portion of the
aggregates was removed by passing the particles through a syringe filter (0.22 mm).
2.2. Labeling HSA-IONPs
The HSA-IONPs were buffer-changed with borate buffer (50 mM, pH 8.5) on
a PD-10 column. For coupling, Cy5.5-NHS in DMSO was added into the particle
solution at a 5:1 dye:HSA ratio, with the reaction carried out in darkness for 30 min.
Subsequently, DOTA-NHS in DMSO was added, at a 5:1 DOTA:HSA ratio, and the
reaction went on overnight in darkness. Details regarding the DOTA labeling have
been reported elsewhere [21,22]. The solution was purified through a PD-10 column,
and the solvent was exchanged to PBS buffer (pH 7.4).
2.3. Cell culture and animal model
A U87MG human glioblastoma cell line was purchased from the American Type
Culture Collection (ATCC) and cultured with ATCC-formulated Eagle’s Minimum
Essential Medium (EMEM) in a cell culture incubator. Athymic nude mice were
purchased from Harlan Laboratories. Approximately 5106 U87MG cells were
inoculated subcutaneously into the front flank of each mouse, and in vivo imaging
was carried out 3 weeks after the inoculation (when the tumor size reached about
100 mm3). All animal work was conducted following a protocol approved by the
Stanford University Administrative Panel on Laboratory Animal Care (APLAC).
2.4. In vivo and ex vivo NIRF imaging
The mice were anesthetized with isoflurane (IsoFlo; Abbott Laboratories) and
were i.v. injected with HSA-IONPs at a dose of 10 mg Fe/kg. The NIRF images were
acquired on an IVIS 200 imaging system at 1 h, 4 h and 18 h post injection. At the end
of the 18 h scan, the mice were sacrificed, and the tumors as well as the major organs
were collected and subjected to ex vivo NIRF imaging with the IVIS 200 system.2.5. Small-animal PET imaging
The details of small-animal PET imaging, and the region-of-interest (ROI) analysis
have been reported previously [21,22]. The 64Cu-labeled HSA-IONPs were purified
with a PD-10 column and injected intravenously into the U87MG tumor-bearing mice
at a dose of 10 mg Fe/kg. PET scans were performed with a microPET R4 rodent
scanner (Siemens Medical Solutions) at 1 h, 4 h and 18 h post injection (p.i.) time
points. For each scan, 3-dimensional ROIs were drawn over the tumor and organs on
decay-corrected whole-body coronal images. The average radioactivity concentration
was obtained from the mean pixel values within the ROI volume, and was converted
to counts per milliliter per minute by using a predetermined conversion factor [21,23].
Given a tissue density of 1 g/mL, the counts per milliliter per minute were converted
to counts per gram per minute, and the values were divided by the injected dose to
obtain the imaging-ROI-derived percentage injected dose per gram (%ID/g). At the end
of the 18 h scan, the mice were sacrificed, and the tumors as well as the major organs
were collected and subjected to an ex vivo PET scan.
2.6. Small-animal MR imaging
HSA-IONPs were injected through the tail vein (10 mg Fe/kg) of the anesthetized
mice. T2 weighted fast spin-echo images were acquired on a 7.0-T small-animal
system (GE Healthcare), before and at 18 h after the particle injection, with the
following parameters: TE 40 ms, TR 3000, thickness 1 mm, FOV 6 6, NEX 6.0, Echo
1/1. Signal intensities were measured in defined ROIs with Image J (National Insti-
tutes of Health).
2.7. Ex vivo fluorescence examination on the tumor sections
The U87MG tumor-bearing mice were injected with HSA-IONPs at a dose of
10 mg Fe/kg. At the 18 hp.i. time point, 200 mg fluorescein isothiocyanate (FITC)-
labeled tomato lectin (Thermo Fisher Scientific, Rockford, IL) was injected, and the
mice were sacrificed 10 min later. The tumors were harvested and put into
optimal-cutting-temperature (o.c.t.) compound to prepare frozen tissue blocks.
The tissue blocks were sectioned into 40 mm thick slices and stored in darkness
until imaging. The fluorescence images were taken on an Axiovert 200M micro-
scope (Carl Zeiss).
2.8. Prussian blue staining of tumor and major organ sections
Frozen organ blocks were sectioned into 10 mm slices. Before staining, the tissue
slides were warmed up at room temperature for 20 min and fixed with ice-cold
acetone for 5 min. Afterwards, they were dried and immersed in staining solution
(a mixture of 20% hydrochloric acid and 10% potassium ferrocyanide solution in a 1:1
volume ratio) for 40 min. Next, the slides were washed gently with PBS and coun-
terstained with eosin for 5 min. After that, they were dehydrated consecutively with
90%, 95% and 100% EtOH (3 min each), cleaned with xylene, and finally mounted
with Permount medium.
2.9. Prussian blue/CD31 and Prussian blue/F4/80 double staining
Frozen U87MG tumor tissues were sectioned into 10 mm slices and stored
at 80 C. Before examination, the specimens were warmed up for 20 min at room
temperature and fixed with ice-cold acetone for 5 min. After fixation, slides were
incubated with 0.3% H2O2 solution in PBS for 10 min to block endogenous peroxidase
activity, and were rinsed 3 times with PBS (2 min each). Primary rat anti-mouse
CD31 antibody diluent (1:50) was subsequently applied to the tissue sections, and
the incubation was carried on for 1 h in a humid chamber. After rinsing with PBS
(3 2 min), a biotinylated anti-rat IgG secondary antibody solution (1:50) was
applied, and the tissue was incubated for 30 min. The slides were rinsed again with
PBS and were incubated with streptavidin-HRP solution for 30 min. After another
washing cycle, the slides were developed with 3,30-diaminobenzidine (DAB)
substrate solution until the desired color intensity was reached. The resulting slides
were subjected to Prussian blue staining with the procedure described above.
Double staining of Prussian blue and F4/80 was conducted in a similar manner,
except for changing the antibody to primary rat anti-mouse F4/80.
3. Results
3.1. Synthesis and characterization of HSA-IONPs
The IONPs were made from pyrolysis with a core diameter of
15 nm (Fig. 2a). The particles were coated with one layer of oleate
and wouldn’t disperse in water. To render them water-soluble, we
conducted a two-step surface modification: in the first step, an
excess amount of dopamine was utilized, which replaced the oleate
coating by forming chelates with the surface Fe atoms [8,13,24];
Fig. 1. Schematic illustration of the multi-funtional HSA-IONPs. The pyrolysis-derived IONPs were incubated with dopamine, after which the particles became moderately
hydrophilic and could be doped into HSA matrices in a way similar to drug loading.
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dropwise into HSA aqueous solution, where HSA was adsorbed onto
the amine-rich particle surface (Fig. 1). The iron oxide cores
remained almost intact throughout the modification, as little
change in size or morphology was observed (Fig. 2b). The hydro-
dynamic size, on the other hand, increased from 19.0 0.9 nm
(hexane solution, w2 nm oleate coating and 15 nm core) to
29.41.2 nm (in PBS), which we attributed to the additional HSA
coating (Fig. S1, Supporting Information). The HSA-IONPs are highly
stable in aqueous environment, and showed little hydrodynamic
size change when incubated in PBS buffer at 37 C for 48 h (Fig. 2c).
Although the details of the particle-HSA interaction are unknown at
this stage, we postulate that the electrostatic forces between the
albumin (pI 5.0) and the aminated particle surface play an impor-
tant role. Compared with IONPs that are made from co-precipita-
tion methods (such as Feridex), those made from pyrolysis are
known to have better crystallinity, hence larger r2 relaxivities [25].
To confirm this, we performed a phantom study and found that
HSA-IONP has an r2 of 313 mM
1 s1, much higher than that of
Feridex (123 mM1 s1) (Fig. 2d).To assess the constitution of HSA-IONP particles, the protein and
Fe concentrations were determined respectively by Bradford
protein assay and inductively coupled plasma (ICP) spectrometry.
The Fe concentration was further converted to particle concentra-
tion based on the assumption that each IONP was made of
magnetite with a diameter of 15 nm and a density of 5.2 g/cm3 [3].
The HSA/IONP mole ratio was determined to be about 10:1, i.e. on
each IONP there are about ten HSA protein molecules (Fig. 1). Next,
Cy5.5 and DOTA were coupled to the particle surface. In a previous
study, we demonstrated that about 10 lysines from each HSA can be
utilized for chemical coupling [20,26]. Herein, we mixed the
nanoparticles with Cy5.5-NHS and DOTA-NHS at a 1:5:5 HSA:-
Cy5.5:DOTA ratio to allow double labeling. According to the radio/
fluorescent activities, it was estimated that there are about 20
Cy5.5/DOTA on each particle surface.
3.2. Small-animal NIRF/PET/MR triple imaging
The animal model was established by subcutaneously inocu-
lating 5106 U87MG cells into the front flank of each mouse, and
Fig. 2. (a) TEM of oleate coated IONPs in hexane. (b) TEM of the HSA-IONPs in water. (c) Hydrodynamic size change of the HSA-IONPs when incubating in PBS at 37 C for 48 h,
monitored by DLS. (d) r2 relaxivity evaluations with HSA-IONPs and Feridex.
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were injected i.v. at a dosage of 10 mg Fe/kg, and PET/NIRF images
were acquired 1 h, 4 h and 18 h post injection (Fig. 3). For NIRF
results, a clear tumor delineation was observed at the 1 h time
point, and the contrast improved over time, and the tumor/muscle
ratio increased from 1.98 0.20 at 1 h to 2.52 0.27 at 4 h, and to
3.08 0.28 at 18 h (n¼ 3/group) (Fig. 3a). A similar tumor homingFig. 3. (a) Representative in vivo NIRF images of mouse injected with HSA-IONPs. Images w
injected with HSA-IONPs. Images were acquired 1 h, 4 h and 18 h post injection. (c) MRI imtrend was observed in PET results, showing a gradually elevated
tumor uptake of 5.46 0.64, 6.110.70 and 8.45 0.86% ID/g at
the 1, 4 and 18 h time points. Notably, compared with NIRF results,
the PET imaging shows much higher tumor/muscle ratios of
4.55 0.42, 5.36 0.61 and 8.28 0.90 at 1 h, 4 h and 18 h,
respectively (Fig. 3b). Such improvement was mainly attributed to
a cleaner background of PET [4]. In accord with these observations,ere acquired 1 h, 4 h and 18 h post injection. (b) In vivo PET imaging results of mouse
ages acquired before and 18 h post injection.
Fig. 4. (a) Ex vivo PET imaging on tumor and the major organs. (b) Ex vivo NIRF imaging on tumor and the major organs.
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a signal drop of 29.9 4.2% at the tumor sites (Fig. 3c). A clear
inhomogeneous particle distribution pattern was observed with
MRI [27,28], but PET and NIRF results showed homogeneous
intensities at the tumor area. Immediately after the 18 h scan, the
mice were sacrificed and ex vivo PET and NIRF imaging were per-
formed on the allograft tumors as well as on the major organs
(Fig. 4). Besides substantial intensities from tumor, high tracer
accumulation in the liver was also found by both imaging tech-
niques, with liver/muscle ratios of 6.42 0.78 and 28.2 2.9 from
NIRF and PET results, respectively. Again, such a discrepancy was
mainly attributed to the relatively high background of NIRF
imaging.3.3. Histology studies
To improve our understanding of the particle distribution at the
tissue and sub-tissue levels, we performed a series of immunos-
tainings. An enrichment of the particles in tumor was found with
Prussian blue staining, which correlated well with the ex vivo PET/
NIRF results (Fig. 5a). Notably, the particles showed an inhomoge-
neous distribution pattern across the tumors, supporting the MRI
observation. Next, using CD31 as a vasculature marker, Prussian
blue and CD31 double staining were conducted on the tumor
sections. As displayed in Fig. 6a, although some particles were
found in the vascular lumen, most were found outside of the
vessels, indicating a high extravasation rate. This observation was
supported by a separate study, where Cy5.5 labeled HSA-IONPs
were injected i.v. into U87MG bearing mice, followed by the
administration of FITC-lectin, a blood vessel marker, at the 18 p.i.Fig. 5. (a) Prussian blue staining on tumor sections. Blue spots, representing the Fe conten
pattern. (b) Ex vivo examination of tumor sections by fluorescence microscope. Cy5.5 labe
tomato lectin was injected, and the mice were sacrificed 10 min later. The overlaid image w
colors represent Cy5.5-HSA-IONPs, FITC-lectin and DAPI, respectively.time point. The ex vivo assessment of the tumor samples (Fig. 5b)
found little correlation between the particles (red) and the vascu-
lature (green); rather, most of the particles stayed outside of
vasculature. It is worth noting that, due to limited resolution, only
the spots with particle aggregates can be seen by fluorescence
microscopy. Taking that into account, the ex vivo fluorescence
examination demonstrated a particle distribution pattern similar to
that of the Prussian blue staining results. To further evaluate
whether the trapping of particles at the tumor site was caused by
macrophage uptake, Prussian blue and F4/80 double staining were
performed on the tumor sections (Fig. 6b). Although some co-loc-
alization between the two staining results was found, the retention
of most of the particles was found to be non-related to macrophage
uptake.4. Discussion
IONPs must have moderate hydrophobicity in order to be doped
into HSA matrices. Unfortunately, traditional IONPs made from
either co-precipitation methods or pyrolysis methods do not have
this property. In this study, by simply incubating with dopamine, we
obtained an IONP formula that can be dispersed in polar solvents,
such as DMSO, but is not strongly water-soluble. In a way that
resembles a drug loading process, these particles were added into
HSA solution, where they adsorb one layer of HSA, yielding
complexes that are stable under physiological conditions. Even just
from the particle preparation perspective, this method is mean-
ingful, affording an easy, reliable and high-throughput way to make
highly stable IO nanoconjugates. More importantly, by sharingts, were found across the tumor and the distribution was found in an inhomogeneous
led HSA-IONPs were i.v. injected into mice. Then at the 18 h time point, FITC labeled
as constructed by MataMorph Imaging Processing software. The red, green and blue
Fig. 6. (a) CD31 and Prussian blue double staining of the tumor samples. Some particles were found within the vessels (upper left), while many others managed to extravasate
(lower left). (b) F4/80 and Prussian blue double staining of the tumor samples. Although some particles were found within macrophages (upper right), most of them were found
independent of macrophages (lower right).
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loaded with drug molecules to yield theranostic agents.
To evaluate the pharmacokinetics, the HSA-IONPs were dually
labeled with both 64Cu-DOTA chelator and Cy5.5 to make them
MRI/PET/NIRF triple active. This approach was based on the
consideration that each of these three modalities has advantages,
and an integrated approach may lead to synergistic benefits [29].
For instance, MRI offers a high spatial resolution and, as proven in
this study, and can provide a better description of the particle
distribution pattern than either PET or NIRF. However, MRI has the
issue of limited sensitivity. To compensate for this drawback, PET
and NIRF reporters were added. Between these two, PET provides
a better signal-to-noise ratio. NIRF, on the other hand, can be
visualized both in vivo by an IVIS system and ex vivo by fluorescence
microscopy, playing a unique role of bridging the in vivo and
histological observations. By combining the information gathered
from all the aspects, we confirmed that the HSA-IONPs have not
only a high retention rate, but also a good extravasation rate and
a low macrophage uptake rate at the tumor area. All of these
observations are encouraging, considering the ultimate goal of
using these particles as theranositc nanoplatforms.
We attributed the profound tumor retention of the particles
mainly to the more permeable vasculature environment at the
tumor site, i.e. the EPR effect (enhanced permeability and retention
effect) [20]. Also, the interaction of the HSA sheath with cell surface
glycoprotein (gp60) receptor (albondin) and/or SPARC (secreted
protein acid and rich in cysteine) should have played a role, which
facilitated the transportation of the particles [20,30–32]. But
neither of the mechanisms would have worked without a reason-
able circulation half-life of the particles. Compared with traditional
formulas, the HSA-IONPs appear to be less provocative to the
immune secretion and possess prolonged circulation half-life,
probably due to their HSA protection. In one analysis, HSA-IONPs
and Feridex at the same dosage (10 mg Fe/kg) were injected i.v. into
mice, and MRI was used to monitor the signal changes in liver. For
Feridex, the signal drop in liver maximized at 1 h and started
regaining at the 2 h time point. On the contrary, in the HSA-IONP
group, the contrast enhanced gradually and the effect lasted for
more than 24 h, indicating a much improved circulation half-life
(Fig. S2, Supporting Information). It is worth noting that ICP
emission spectrometry, a potent means frequently used to evaluate
inorganic nanoparticle biodistribution [33,34], is not applicable in
this study, due to the high contribution of endogenous Fe. Also,
although researchers have utilized Fe isotope as precursors in
making IONPs [35], these efforts were limited to particles made
from co-precipitation and are technically challenging for applica-
tion to pyrolysis-based IONP preparation and analysis.One major concern of this study is the possibility that the HSA
sheath, although seemingly stable in the in vitro analysis, may
detach from the particle surface in the complex in vivo environment
and lead to false-positive observations. However, the ex vivo fluo-
rescence examination (Fig. 5b) showed a particle distribution
pattern that was very similar to the Prussian blue staining results,
suggesting that coating detachment was not severe, if it occurred.
The results of this study show the potential benefits of this
system in a theranostic context. The preliminary tests have
confirmed that drug molecules, such as PTX, can be co-loaded into
such nanosystems without significantly changing the particles’
physical properties (Fig. S1, Supporting Information). Due to the
large number of variables, such as original particle size, particle to
drug ratio, loading buffer pH, etc., it will be non-trivial to optimize
formulas (e.g., optimal drug loading rate and stability) with even one
particular drug molecule. It was worth pointing out that, although
IONPs may occupy certain binding sites of HSA, they may not
necessarily compromise the loading efficacy of the drug molecules.
An amine-rich coating layer could even enhance the particles’ ability
to interact electrostatically with drug molecules. Furthermore, it may
be possible to incorporate some molecules for which HSA is not
a favorable excipient, such as siRNA, into such nanosystem.
5. Conclusions
In the current work, we introduced a two-step, dopamine-plus-
HSA strategy to yield stable nanoconjugates. Unlike the traditional
IONP surface modification method, this approach allows the
particles to be loaded into HSA matrices in a way that resembles
Abraxane preparation. Imaging and histological examinations
found that the particles have a good retention rate and a high
extravasation rate at the tumor sites, due it is believed to the
compact HSA coating. In addition, it was confirmed that particle
accumulation at the tumor sties is not caused by macrophage
uptake.
Appendix. Supplementary data
Supplementary data associated with this article can be found in
the online version, at doi:10.1016/j.biomaterials.2010.01.010.
Appendix
Figures with essential colour discrimination. Most of the figures
in this article may be difficult to interpret in black and white. The
full colour images can be found in the on-line version, at doi:10.
1016/j.biomaterials.2010.01.010.
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